ACM maintains a state-of-the-art central microbiology lab, and our experts have outstanding knowledge of the complete analytical cycle of clinical microbiology.
ACM Global Laboratories is at the forefront of many technological advances. We can help you best optimize the yield of microbiologic cultures at every stage, from pre-analytical sample collection and handling to lab analysis and post-analytical reporting. Our team is able to design and develop solutions for virtually any clinical trial involving infectious diseases, aided by our microbiology laboratory. Our microbiology and molecular diagnostic services include:
Our usual approach to antimicrobial trials includes the receipt and processing of bacterial or yeast isolates. We perform bacterial and yeast identifications using MALDI-TOF Mass Spectrometry, which can shorten the identification process of hundreds of different bacteria and yeast to mere hours. This is a dramatic improvement compared to the multiple days required with more traditional biochemical techniques. We also set up customized susceptibility testing for the sponsor’s antibiotic, and any other comparator antibiotics, as required. Our laboratory can also perform molecular analysis of isolates. If additional comprehensive analysis is required, we’ll partner with more specialized labs.
We have more than 40 years of experience and 550 laboratory professionals, enabling us to efficiently manage and provide expert analysis for your clinical trial research programs. Our expert staff includes an American Board of Medical Microbiology-certified Director of Microbiology and Molecular Diagnostics; a staff of microbiology specialists; and dedicated project managers.
Clients choose us for the knowledge and experience we have to conduct their trials as well as for our capacity to move their specimens through the process quickly and efficiently without impacting the data. The tests we are most frequently asked to perform are:
Our services are frequently requested for trials involving the gastrointestinal system, including such conditions as ulcerative colitis, Crohn’s disease and IBS. Throughout the process, we adhere steadfastly to the regulatory mandates and program protocols of Phase II and Phase III testing, to ensure the most accurate and repeatable results. These are just a few reasons why 75 percent of the new studies we’ve been awarded are with clients we’ve worked with in the past two years.